Document is current
Any future updates will be listed below
-
Authors
Lo, David Y.
Ahmadzada, Boyukkhanim
Stachel, MacKenna A.
Schaefer, Melia
Ashraf, Usman
Wagner, John I.
Vanderslice, Ethan J. https://orcid.org/0000-0002-6273-921X
Tornquist, Madie
Mariakis, Kendra
Halsten, Peggy
Lindsay, Christopher D.
Beck, Emily C.
Nyberg, Scott L. https://orcid.org/0000-0002-5005-3050
Ross, Jeffrey J. https://orcid.org/0009-0000-6282-2059
- License Information
-
More Information
Article History
Received: 20 October 2023
Accepted: 12 November 2024
First Online: 5 December 2024
Competing interests
: The authors declare the following competing interests: D.Y.L., M.A.S., M.S., J.I.W., E.J.V., U.A., C.D.L., K.M., P.H., E.C.B., and J.J.R. are or were employees of Miromatrix Inc., a subsidiary of United Therapeutics. United Therapeutics is a publicly funded company and owns the exclusive patent rights for the perfusion decellularization and recellularization technologies utilized in this study. The remaining authors declare no competing interests.
